NCT02543229 - Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 7, 2017

Study Completion Date

September 30, 2017

Conditions

Eye DiseasesMacular DegenerationRetinal DiseasesRetinal DegenerationNeovascularization, Pathologic

Interventions

DRUG

OPT-302

OPT-302 will be administered by intravitreal injection once every month for 3 months

DRUG

Lucentis™

Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Trial Locations (14)

28210

Opthea Investigative Site, Charlotte

29169

Opthea Investigative Site, West Columbia

32503

Opthea Investigative Site, Pensacola

33800

Opthea Investigative Site, Winter Haven

33912

Opthea Investigative Site, Fort Myers

44122

Opthea Investigative Site, Cleveland

67214

Opthea Investigative Site, Wichita

76087

Opthea Investigative Site, Willow Park

79606

Opthea Investigative Site, Abilene

85014

Opthea Investigative Site, Phoenix

90211

Opthea Investigative Site, Beverly Hills

93454

Opthea Investigative Site, Santa Maria

95819

Opthea Investigative Site, Sacramento

07003

Opthea Investigative Site, Bloomfield

All Listed Sponsors

lead

Opthea Limited

INDUSTRY